May 2010 Vol XXXIV Issue 5
NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #84
Buried Bumper Syndrome: Can We Prevent It?This article focuses on prevention of BBS. Once recognized, a buried bumper should be removed even if the patient is asymptomatic, because of the risks of tube impaction in the abdominal wall and/or gastric perforation, as illustrated in the case report included in this review.
INFLAMMATORY BOWEL DISEASE, SERIES #61
Granulocyte, Monocyte Apheresis Treatment in Pediatric Inflammatory Bowel DiseaseThis article discusses the treatment of chronic bowel diseases in pediatric patients. The number of young patients with inflammatory bowel disease (IBD), comprising Crohn's disease (CD) and ulcerative colitis (UC), is increasing markedly in Western countries; during the last twenty years the incidence of patients has doubled in Scandinavia. Preliminary results are promising and encouraging to future research in the treatment of pediatric ulcerative colitis and Crohn's disease.
A SPECIAL ARTICLE
Efficacy of Vitamin E and Vitamin C in the Treatment of Nonalcoholic SteatohepatitisThe etiology of nonalcoholic steatohepatitis (NASH) is not completely understood, but a "2-hit" theory has been proposed, which includes steatosis and oxidative stress. This retrospective, single-center study determined the effects of vitamins E (400–800 IU/day) and C (500–1000 mg/day) in lowering serum aminotransferases in NASH patients.
A CASE REPORT
Aeromonas Hydrophila: A Rare Cause of Biliary SepsisThis case presents a patient with an insidious onset of cholangitic symptoms associated with Aeromonas hydrophila bacteremia.
Departments Section
Quadruple vs. Triple Antibiotic Therapy in H. Pylori Infection
Recent treatment guidelines recommend two first-line therapies for H. pylori infection: PPI, bismuth, tetracycline and metronidazole (quadruple therapy), or PPI, Clarithromycin and amoxicillin (triple therapy). A systematic review and meta-analysis were carried out to compare the efficacy and tolerability of these regimens as first-line treatment of H. pylori.
Colorectal Cancer Risk in Surveillance Colonoscopy
Despite regular colonoscopy, interval colorectal cancer (CRC) may occur. In order to examine the rate of that CRC in a polyp prevention trial continued follow-up study (PPT-CFS), a prospective observational study of that trial's participants began after the trial ended.
PEG Interferon Alfa-2A Plus Ribavirin vs. PEG Interferon Alfa-2B Plus Ribavirin in HCV
In two separate studies, patients with HCV infection were treated by PEG Interferon Alfa-2A plus Ribavirin or PEG Interferon Alfa-2B plus Ribavirin in treatment of chronic hepatitis C virus infection, genotypes 1 to 4. Safety and efficacy were compared using standard schedules.
Treatment of Acute HCV Infection in Injecting Drug Users
The efficacy of treatment of recent HCV infection in IDUs with acute and early chronic HCV was analyzed from data from the Australian Trial in Acute Hepatitis C, which was a prospective study of the natural history and treatment outcomes of patients with recent HCV infection.
C. Difficile Infection Complicating Cirrhosis
To determine the effect of C. difficile-associated disease (CDAD) on outcomes, and to identify risk factors for its development in cirrhosis, case-controlled studies using the D-identified national (nationwide inpatient sample NIS), and an identified liver transplant center database of hospitalized cirrhotics with and without CDAD were performed.
Rifaximin 550 mg Tablets Data Presented at Easl in Vienna
As you are aware, hepatic encephalopathy (HE) is caused by chronic liver failure and results in cognitive, psychiatric and motor impairments, and on March 24, 2010, the U.S. FDA approved XIFAXAN® (rifaximin) 550 mg tablets for the reduction in risk of overt HE recurrence in patients 18 years of age or older.
Expression of Mucin 1 in Pediatric Inflammatory Bowel Disease May Indicate Progression of Illness
Pediatric and Developmental Pathology—Millions of people are afflicted with inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, and 30 percent of new cases occur in childhood. Mucin 1 (MUC1), an epithelial mucin that has been shown to elicit both an immune response and to have altered glycosylation in disease, may be a noninvasive indicator of the progression of these illnesses.
KAPIDEXTM (dexlansoprazole) Renamed DEXILANTTM in U.S. to Avoid Name Confusion
Takeda Pharmaceuticals North America, Inc. announced today that KAPIDEXTM (dexlansoprazole) will be marketed in the United States under the new product trade name DEXILANTTM (dexlansoprazole). The product is indicated for heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE.
